Please login to the form below

Not currently logged in
Email:
Password:

Amryt Pharma appoints new regulatory affairs head

Derval O’Carroll joins the rare disease-focused biopharma from Retrophin

Rare and orphan disease-focused biopharmaceutical group Amryt Pharma has appointed a new head of regulatory affairs in the form of Derval O’Carroll.

O’Carroll has over 25 years’ experience in the pharmaceutical industry and regulatory affairs business. Prior to joining Amryt, she served as senior director of regulatory affairs for rare disease group Retrophin.

Her previous roles have seen her provide regulatory, strategic and operational input to product teams and managing development-stage and commercial products.

Prior to her time at Retrophin, O’Carroll spent eleven years as a managing consultant at Real Regulatory, a consultancy specialising in European regulatory affairs, quality management systems and supply chain operations compliance.

Her new role will see her take responsibility for engagement with regulatory agencies and she will examine opportunities to pursue new orphan indications for Amryt’s Epidermolysis bullosa candidate.

Dr Joe Wiley, chief executive officer or Amryt Pharma, said: “We are delighted to further strengthen our senior management team with the appointment of Derval as head of regulatory affairs.

“Her expertise will be particularly valuable as we plan for completion of our ongoing AP101 phase III trial in EB.”

1st February 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...
Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...

Infographics